1st Quarter - Report

BOSTON SCIENTIFIC CORPORATION for BOSTON SCIENTIFIC CORPORATION

Firm
Client
Income
—
Expenses
$380,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

5 issue areas, each in the filer's own words, with who lobbied on it and where.

Transportation TRA

2023 Reauthorization of the Federal Aviation Administration - Limitations on aircraft transportation of lithium batteries. House, Senate, Pipeline & Hazardous Materials Safety Admin (PHMSA) Interim Final Rule (IFR) HM 224I. -Issued by PHMSA to revise Hazardous Materials Regulations for lithium cells & batteries transported by aircraft.

LobbyistCovered position, as disclosed
ISAAC A FORDJOUR —
STEVEN NEIL LAPIERRE —
CHRISTOPHER LEE TIMMERMAN —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Labor Issues/Antitrust/Workplace LBR

The Workforce Mobility Act of 2023 (S. 220/ H.R. 731) - prohibits the use of non-compete agreements in the context of commercial enterprises except under certain circumstances. Advocacy to exclude select leaders and employees with access to intellectual property and trade secrets from proposed non-competes ban. FTC Non-Compete Clause Proposed Rulemaking (Matter Number P201200) - proposed rule preventing employers from entering into non-compete clauses with workers and requiring employers to rescind existing non-compete clauses. Advocacy to exclude select leaders and employees with access to intellectual property and trade secrets from FTC's proposed rule.

LobbyistCovered position, as disclosed
CAMERON BAKER New —

Contacted: SENATE; Federal Trade Commission (FTC); HOUSE OF REPRESENTATIVES

Bills named: H.R. 731 (118th), S. 220 (118th)

Taxation/Internal Revenue Code TAX

Research and Development (R&D) Expensing - advocacy for legislation to return to pre-2022 R&D expensing rules. OECD 2 Pillar Framework Implementation- International tax provisions specifically regarding the global minimum tax, interest deductions, and R&D expense deductibility.

LobbyistCovered position, as disclosed
ISAAC A FORDJOUR —
STEVEN NEIL LAPIERRE —
CHRISTOPHER LEE TIMMERMAN —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Health Issues HCR

Ensuring Patient Access to Critical Breakthrough Products Act of 2023 (H.R. 1691) - Legislation to create automatic CMS coverage for devices approved via FDA's breakthrough pathway. House/Senate Implementation of Comprehensive Addiction & Recovery Act (CARA) Law to address the National Opioid epidemic. Specifically, Advocacy for FDA approved alternative treatments for Chronic Pain. 2023 Reauthorization of the SUPPORT for Patients and Communities Act (Public Law 115-271)- Advocacy for reauthorization of the SUPPORT Act, specifically for FDA approved alternative treatments for Chronic Pain, and medical device's role in the opioid epidemic. CMS rulemaking for Transitional Coverage of Emerging Technologies (TCET)- advocacy for a new, voluntary Transitional Coverage of Emerging Technologies (TCET) pathway that provides national Medicare coverage for Breakthrough-designated technologies, beginning on the date of FDA market authorization. Implementation of the Food and Drug Omnibus Reform Act of 2022 (Public Law 117-328) - advocacy efforts on Medical Device User Fee Amendments (MDUFA) reauthorization, riders & device shortages. Implementation of the Chips and Science Act (Public Law 117-167) - advocacy to establish a $29 billion fund at the National Science Foundation to fund research in the areas of AI and medical technology. Additional efforts on semiconductor and raw materials shortages, device shortage reporting, resilient supply chain, domestic incentives and Buy America proposals. 21st Century Cures Act 2.0 (CURES 2.0) - legislation to advance medical research and to foster a new era of medical innovation and prepare for future pandemics and promote health equity 2023 Reauthorization of the Pandemic and All-Hazards Preparedness Act (PAHPA) (Public Law 109-417) - advocacy on risk mitigation plans and voluntary shortage reporting related to medical device supply chains. EPA Rulemaking Restricting Ethylene Oxide (ETO) - Proposed rulemaking to place more-stringent limits on emissions and institute new monitoring requirements for ethylene oxide (ETO). Advocacy efforts include educating lawmakers on the importance of ETO in the sterilization of medical devices and potential shortages of sterile medical devices if EPA's proposed changes are enacted.

LobbyistCovered position, as disclosed
ISAAC A FORDJOUR —
STEVEN NEIL LAPIERRE —
CHRISTOPHER LEE TIMMERMAN —

Contacted: SENATE; Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; Office of Management & Budget (OMB)

Bills named: H.R. 1691 (118th)

Veterans VET

VHA Directive 2009-053 - Pain care directive - working to increase veteran access to pain specialists and FDA approved alternative treatments in the VHA Public Law No. 113-146 - Veterans Access, Choice, and Accountability Act: Implementation of law to allow veterans to seek healthcare from non-VA facilities if unable to receive care from the VA in a timely manner. National Pain Strategy - Encouraging adaption of the NIH's National Pain Strategy Medial device supply chain procurement - VHA patient access to Med Technology as VHA migrates to new sourcing methodology Implementation of Comprehensive Addiction and Recovery Act (CARA) law to improve the quality of Pain Care provided to veterans. Purchase Order Prompt Pay - Ensures the VA pays bills in accordance with the law. Public Law No. 115-407 - Veterans Benefits and Transition Act of 2018 - specifically the inclusion and implementation of Rep. Bergman's VA MedSurg Purchasing Stabilization Act - VA device formulary; requires clinical expertise development

LobbyistCovered position, as disclosed
ISAAC A FORDJOUR —
STEVEN NEIL LAPIERRE —
CHRISTOPHER LEE TIMMERMAN —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.